VFQ-25 subscales at 12 months after treatment | Stereopsis at 12 months after treatment | |||
TNO stereo test | Titmus stereo test | |||
r | P values | r | P values | |
General health | −0.18 | 0.31 | −0.11 | 0.54 |
General vision | −0.05 | 0.81 | −0.05 | 0.77 |
Ocular pain | −0.01 | 0.94 | 0.07 | 0.69 |
Near activities | −0.35 | 0.053 | −0.26 | 0.15 |
Distance activities | −0.41 | <0.05* | −0.15 | 0.41 |
Social functioning | −0.20 | 0.27 | −0.18 | 0.33 |
Mental health | −0.27 | 0.14 | −0.24 | 0.20 |
Role difficulties | −0.20 | 0.28 | −0.10 | 0.58 |
Dependency | −0.22 | 0.22 | −0.29 | 0.11 |
Driving | −0.20 | 0.35 | −0.04 | 0.85 |
Colour vision | −0.21 | 0.26 | −0.24 | 0.18 |
Peripheral vision | −0.21 | 0.24 | −0.04 | 0.84 |
VFQ-25=25 Item Visual Function Questionnaire.
*Significant correlation between VFQ-25 subscales at 12 months after treatment and stereopsis at 12 months after treatment (Spearman’s correlation coefficient).
VFQ-25, 25-item National Eye Institute Visual Function Questionnaire.